Q2 2022 Earnings Estimate for Vincerx Pharma, Inc. Issued By SVB Leerink (NASDAQ:VINC)

Vincerx Pharma, Inc. (NASDAQ:VINCGet Rating) – Research analysts at SVB Leerink boosted their Q2 2022 earnings per share estimates for Vincerx Pharma in a research note issued to investors on Monday, June 6th. SVB Leerink analyst J. Chang now expects that the company will post earnings per share of ($0.92) for the quarter, up from their previous estimate of ($1.04). SVB Leerink has a “Outperform” rating and a $6.00 price objective on the stock. SVB Leerink also issued estimates for Vincerx Pharma’s Q3 2022 earnings at ($0.78) EPS, Q4 2022 earnings at ($0.66) EPS, FY2022 earnings at ($3.15) EPS and FY2023 earnings at ($1.92) EPS.

Vincerx Pharma (NASDAQ:VINCGet Rating) last issued its earnings results on Tuesday, March 29th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.08.

VINC has been the topic of several other reports. Chardan Capital cut their target price on shares of Vincerx Pharma from $11.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday. Cantor Fitzgerald dropped their price objective on shares of Vincerx Pharma from $22.00 to $8.00 in a research note on Wednesday. B. Riley dropped their price objective on shares of Vincerx Pharma from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday. Zacks Investment Research lowered shares of Vincerx Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. Finally, HC Wainwright raised their price objective on shares of Vincerx Pharma from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, March 29th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.18.

Shares of NASDAQ VINC opened at $1.94 on Thursday. Vincerx Pharma has a 12-month low of $1.40 and a 12-month high of $18.43. The company’s fifty day simple moving average is $2.49 and its 200 day simple moving average is $5.79.

Several hedge funds have recently made changes to their positions in the company. Long Focus Capital Management LLC purchased a new position in shares of Vincerx Pharma in the fourth quarter worth about $1,429,000. Hollencrest Capital Management purchased a new position in shares of Vincerx Pharma in the fourth quarter worth about $102,000. Hudson Bay Capital Management LP bought a new position in shares of Vincerx Pharma in the third quarter valued at approximately $3,005,000. Allspring Global Investments Holdings LLC bought a new position in shares of Vincerx Pharma in the fourth quarter valued at approximately $83,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Vincerx Pharma by 12.3% in the fourth quarter. Russell Investments Group Ltd. now owns 63,450 shares of the company’s stock valued at $644,000 after acquiring an additional 6,934 shares during the period. Institutional investors own 78.01% of the company’s stock.

Vincerx Pharma Company Profile (Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Featured Articles

Earnings History and Estimates for Vincerx Pharma (NASDAQ:VINC)

Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.